Abstract
Breast cancer is one of the most common types of cancer in women, and is the second leading cause of cancer-related deaths in the United States. Chemoprevention using phytoestrogens (PEs) for breast cancer may be a valid strategy. PEs are phytochemicals with estrogen-like structures and can be classified into four types: isoflavones, lignans, stilbenes and coumestans. They are widely distributed in diet and herbs and have shown anti-cancer activity via mechanisms including estrogen receptor modulation, aromatase inhibition, and anti-angiogenesis. Genistein, daidzein and resveratrol are some of the most studied PE examples. Quality control in product manufacturing and clinical study design is a critical issue in developing them as clinically effective chemopreventive agents for breast cancer.
Keywords: Phytoestrogens, Breast cancer, Chemoprevention, Estrogen receptor modulator, Aromatase inhibitor, Genistein, Daidzein, Glycitein, Equol, Matairesinol, Secoisolariciresinol, Sesamin, Enterolactone, Enterodiol, Resveratrol, Coumestrol
Anti-Cancer Agents in Medicinal Chemistry
Title:Developing Phytoestrogens for Breast Cancer Prevention
Volume: 12 Issue: 10
Author(s): Mandy M. Liu, Ying Huang and Jeffrey Wang
Affiliation:
Keywords: Phytoestrogens, Breast cancer, Chemoprevention, Estrogen receptor modulator, Aromatase inhibitor, Genistein, Daidzein, Glycitein, Equol, Matairesinol, Secoisolariciresinol, Sesamin, Enterolactone, Enterodiol, Resveratrol, Coumestrol
Abstract: Breast cancer is one of the most common types of cancer in women, and is the second leading cause of cancer-related deaths in the United States. Chemoprevention using phytoestrogens (PEs) for breast cancer may be a valid strategy. PEs are phytochemicals with estrogen-like structures and can be classified into four types: isoflavones, lignans, stilbenes and coumestans. They are widely distributed in diet and herbs and have shown anti-cancer activity via mechanisms including estrogen receptor modulation, aromatase inhibition, and anti-angiogenesis. Genistein, daidzein and resveratrol are some of the most studied PE examples. Quality control in product manufacturing and clinical study design is a critical issue in developing them as clinically effective chemopreventive agents for breast cancer.
Export Options
About this article
Cite this article as:
M. Liu Mandy, Huang Ying and Wang Jeffrey, Developing Phytoestrogens for Breast Cancer Prevention, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/187152012803833062
DOI https://dx.doi.org/10.2174/187152012803833062 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma
Current Cancer Drug Targets Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Biological Evaluation and Molecular Modeling of 3,4-dihydropyrimidine- 2(1H)-one Derivatives as Cytotoxic Agents on Breast Cancer In Vitro
Letters in Drug Design & Discovery Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Computational Bioactivity Analysis and Bioisosteric Investigation of the Approved Breast Cancer Drugs Proposed New Design Drug Compounds: Increased Bioactivity Coming with Silicon and Boron
Letters in Drug Design & Discovery Diffusion Tensor Imaging of Brain Metastases in Patients with Breast Cancer According to Molecular Subtypes
Current Medical Imaging Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry Effect of Low Molecular Weight Heparins and Fondaparinux Upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3
Current Vascular Pharmacology Tricyclic Structures in Medicinal Chemistry: An Overview of their Recent Uses in Non-CNS Pathologies
Mini-Reviews in Medicinal Chemistry Bioavailability Enhancement of Coenzyme Q10: An Extensive Review of Patents
Recent Patents on Drug Delivery & Formulation CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry Propagation on Molecular Interaction Networks: Prediction of Effective Drug Combinations and Biomarkers in Cancer Treatment
Current Pharmaceutical Design New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Significance of 1,3,4-Oxadiazole Containing Compounds in New Drug Development
Current Drug Research Reviews The Emerging Role of microRNA in Stroke
Current Topics in Medicinal Chemistry Breast Cancer and Anesthesia
Current Pharmaceutical Design Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators
Current Topics in Medicinal Chemistry